How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
Firas El Chaer(The University of Texas MD Anderson Cancer Center), Roy F. Chemaly(The University of Texas MD Anderson Cancer Center), Jeffery J. Auletta(Nationwide Children's Hospital)
Cited by 30
Related Papers
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
|Clinical Infectious Diseases|2021|299
Posaconazole: a broad-spectrum triazole antifungal
|The Lancet Infectious Diseases|2005|285